---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-25-000291"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:23:13.834781+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# DexCom appoints Jacob Leach as CEO effective Jan 1, 2026; sets compensation terms

## Summary
- Jacob S. Leach promoted to CEO from President/COO; effective Jan 1, 2026, succeeding Kevin Sayer on medical leave.
- Annual base salary $1,150,000; target bonus 150% of base salary.
- Granted RSUs valued at $7.5M vesting over 3 years; PSUs target $7.5M based on performance.
- Sayer expected to return from medical leave ~March 2026; Foletta remains interim chairman.

## SEC filing metadata
- accession: 0001093557-25-000291
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000291/0001093557-25-000291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000291/dxcm-20251219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-25-000291
- JSON: https://secwatch.observer/filing/0001093557-25-000291.json
- Plain text: https://secwatch.observer/filing/0001093557-25-000291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.